TRAVERE THERAPEUTICS, INC. Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-07-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther · last filed 2018-07-06
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for the quarter ending 2015-09-30 was $518.00K.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for the quarter ending 2015-03-31 was $518.00K.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for fiscal 2017 was $0.00.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for fiscal 2015 was $1.88M.
- TRAVERE THERAPEUTICS, INC. dilutive securities, effect on basic earnings per share, dilutive convertible securities for fiscal 2014 was $0.00.
| Period end | Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities 3 month | Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities 6 month | Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities 9 month | Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-07-06 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-07-06 | |||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $1.88M 10-K · filed 2018-07-06 | |||
| 2015-09-30 | $518.00K 10-Q · filed 2016-11-04 | $1.55M 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | $1.03M 10-Q · filed 2016-08-05 | |||
| 2015-03-31 | $518.00K 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-06 | $0.00 10-Q · filed 2015-11-06 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |